ArticleAdvances in therapy2025
Evaluation of Real-World Treatment Patterns and Healthcare Resource Utilization in Patients with Chronic Refractory Gout in the United States.
Article in Advances in therapy, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
6 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
introductionChronic refractory gout (CRG) is characterized by frequent flares and failure to achieve and/or maintain serum urate levels < 6.0 mg/dL with conventional urate-lowering therapies. This study evaluated the clinical profile, treatment patterns, and healthcare resource utilization (HRU) of patients with CRG in the United States (US) to provide updated information on treatment strategies and burdens.
methodsThis retrospective cohort study analyzed data for patients with CRG (≥ 3 flares within 18 months or a pegloticase prescription following gout diagnosis) between June 2011 and May 2020 in the IQVIA PharMetrics
resultsAmong 969 patients with CRG, 157 had elevated serum urate levels ≥ 6.0 mg/dL during follow-up. All patients had a high comorbidity burden. Most patients in the overall population (57.5%) and in the subset with elevated serum urate during follow-up (73.2%) did not have evidence of achieving serum urate level < 6.0 mg/dL at any point during follow-up, despite use of gout-related medications including allopurinol. Patients in the overall population and the elevated serum urate subset had high use of steroids (77.0% and 79.6%, respectively) and nonsteroid anti-inflammatory drugs (59.3% and 59.9%) to manage gout flares. Additionally, patients had high rates of gout-related HRU, including inpatient admissions [5.7% (overall) and 6.4% (subset)], emergency room visits (12.7% and 15.3%), and outpatient visits (96.8% and 100%).
conclusionDespite the use of urate-lowering medications, patients with CRG had elevated serum urate levels and high HRU, underscoring the need for better treatment and management strategies for CRG to prevent gout flares and minimize long-term damage.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.